Skip to content

Remifentanil Requirement in Patients Receiving Surgical Treatment of Parkinson's Disease

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01992692
Enrollment
62
Registered
2013-11-25
Start date
2012-01-31
Completion date
2013-06-30
Last updated
2013-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Parkinson's disease, remifentanil, deep brain stimulator, cardiovascular response

Brief summary

Parkinson's disease (PD) is one the main neurodegenerative disease with an incidence of about 3% in patients older than 65 years. Anesthesia in PD patients has been focused by several studies for concerning the interactive reaction between anesthetics and anti-Parkinsonian medication or Parkinsonian symptoms. However, our previous experience showed that the patients undergoing pulse generator placement were more prone to be involved in delayed emergence in the recovery room, which had been not reported yet. We speculated that PD patients might be a special population with abnormal pharmacodynamic characters of anesthetics, though no related evidence could be found to support this hypothesis. Therefore, in this project we investigated whether remifentanl requirement to inhibit patients' response to trachea intubation and skin insertion in PD patients undergoing DBS and pulse generator placement was different from non-PD patients undergoing intracranial surgery for reasons other than PD.

Interventions

None listed

Sponsors

Changhai Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult Parkinsonian patients undergoing deep brain stimulator insertion and pulse generator placement * Adult non-Parkinsonian patients undergoing intracranial surgery

Exclusion criteria

* ASA score higher than Class II * predicted difficult airway * alcohol or drug abuser * informed consent was not provided

Design outcomes

Primary

MeasureTime frame
Concentrations required to inhibit response to trachea intubation and skin incisionAnesthesia induction to 5min after skin incision

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026